Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

Pfizer has a well-diversified pipeline, with several late-stage assets to drive medium-term growth. Learn more about PFE ...

Amidst a share value slump and executive turmoil, Pfizer reported a robust quarter thanks in part to Covid-19 drug sales.

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist ...

(Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on ...

(Operator Instructions) Good day, everyone, and welcome to Pfizer's third-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to ...

Pfizer executives are still bullish on the opportunity for its own obesity and diabetes drugs under development, eyeing a potential opening for oral versions and an improved safet ...

At Shionogi, a Japanese pharmaceutical company, executives pointed out that COVID is still flaring in Japan. In Japan, ...

In life, there’s a common expression that also carries over into the dividend investing world: If it seems too good to be true, it usually is ...

Pfizer's pipeline features quite a few promising candidates that could be big winners in the future. CEO Albert Bourla highlighted some of them in the Q3 earnings call. Probably none is as eagerly ...

The company launched a major cost-cutting program and made a significant acquisition, buying cancer specialist Seagen for US$43-billion, a move which Pfizer expects to boost revenue and profits.